BRPI0820793A2 - Seprase como marcador de câncer - Google Patents

Seprase como marcador de câncer

Info

Publication number
BRPI0820793A2
BRPI0820793A2 BRPI0820793-3A BRPI0820793A BRPI0820793A2 BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2 BR PI0820793 A BRPI0820793 A BR PI0820793A BR PI0820793 A2 BRPI0820793 A2 BR PI0820793A2
Authority
BR
Brazil
Prior art keywords
cancer
seprase
types
assessment
specific
Prior art date
Application number
BRPI0820793-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Wolfgang Rollinger
Johann Karl
Jarema Peter Kochan
Markus Roessler
Michael Tacke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07023897A external-priority patent/EP2071337A1/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0820793A2 publication Critical patent/BRPI0820793A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
    • G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
    • G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
    • G01N2333/96411—Serine endopeptidases (3.4.21)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0820793-3A 2007-12-10 2008-12-08 Seprase como marcador de câncer BRPI0820793A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07023897A EP2071337A1 (en) 2007-12-10 2007-12-10 Seprase as a marker for cancer
EP08015310 2008-08-29
PCT/EP2008/010385 WO2009074275A1 (en) 2007-12-10 2008-12-08 Seprase as a marker for cancer

Publications (1)

Publication Number Publication Date
BRPI0820793A2 true BRPI0820793A2 (pt) 2015-06-16

Family

ID=40373548

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0820793-3A BRPI0820793A2 (pt) 2007-12-10 2008-12-08 Seprase como marcador de câncer

Country Status (14)

Country Link
US (1) US8980573B2 (enExample)
EP (1) EP2223115B1 (enExample)
JP (1) JP5563988B2 (enExample)
KR (1) KR101202220B1 (enExample)
CN (1) CN101896818B (enExample)
AT (1) ATE524740T1 (enExample)
AU (1) AU2008335855B2 (enExample)
BR (1) BRPI0820793A2 (enExample)
CA (1) CA2706115A1 (enExample)
DK (1) DK2223115T3 (enExample)
ES (1) ES2372442T3 (enExample)
MX (1) MX2010004671A (enExample)
PL (1) PL2223115T3 (enExample)
WO (1) WO2009074275A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8213005B2 (en) 2003-07-22 2012-07-03 King Saud University Method for discriminating between benign and malignant prostate tumors
JP5298188B2 (ja) * 2008-07-03 2013-09-25 エフ．ホフマン−ラ ロシュ アーゲー 肺癌用マーカーとしてのａｓｃ
JP5763098B2 (ja) 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
DK2666872T3 (en) 2010-02-05 2016-07-25 Astute Medical Inc Methods and compositions for the diagnosis and prognosis of renal injury and renal insufficiency
CA2815356A1 (en) * 2010-10-20 2012-04-26 Rush University Medical Center Lung cancer tests
ES2578477T3 (es) * 2011-03-11 2016-07-27 Roche Diagniostics Gmbh ASC como marcador de la enfermedad pulmonar obstructiva crónica (EPOC)
EP2684049A1 (en) * 2011-03-11 2014-01-15 Roche Diagniostics GmbH Seprase as marker for chronic obstructive pulmonary disease (copd)
CN102435748B (zh) * 2011-11-25 2014-07-16 广东药学院 一种双抗夹心酶联免疫检测试剂盒及其制备方法
WO2013086359A1 (en) 2011-12-08 2013-06-13 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20150023904A (ko) 2012-06-27 2015-03-05 버그 엘엘씨 전립선암의 진단 및 치료에서의 마커의 용도
US9250242B2 (en) 2012-11-09 2016-02-02 Roche Molecular Systems, Inc. In vitro capture and analysis of circulating tumor cells
KR20150090240A (ko) * 2012-11-30 2015-08-05 어플라이드 프로테오믹스, 인크. 결장 종양의 존재 또는 위험의 평가 방법
CA3158996C (en) 2013-01-17 2024-06-04 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US9753037B2 (en) 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
CN103267852B (zh) * 2013-05-15 2015-03-25 中国医学科学院北京协和医院 成纤维激活蛋白α在制备胰腺癌预后试剂盒中的用途
KR101619122B1 (ko) 2013-08-14 2016-05-10 연세대학교 산학협력단 탈메틸화 의존적 ａｓｃ 발현을 촉진시켜서 대장암 종양세포의 사멸감수성을 증진시키는 항암제 병용 투여용 후보물질의 스크리닝 방법
WO2015088947A1 (en) 2013-12-09 2015-06-18 Rush University Medical Center Biomarkers of rapid progression in advanced non-small cell lung cancer
PL230661B1 (pl) * 2014-01-29 2018-11-30 Centrum Onkologii Inst Im Marii Sklodowskiej Curie Oddzial W Gliwicach Metoda predykcyjna in vitro do przewidywania i/lub wykluczenia obecnosci raka pluc, zastosowanie in vitro metody predykcyjnej oraz zestaw testowy do wykrywania in vitro raka pluc
EP2916134B1 (en) 2014-03-05 2017-08-16 Roche Diagnostics GmbH Use of Seprase for differential diagnosis of acute dyspnea
SG11201704660YA (en) 2014-12-08 2017-07-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016146174A1 (en) * 2015-03-17 2016-09-22 Biontech Ag Compositions and methods for diagnosis and treatment of cancer
GB2545361B (en) 2015-04-10 2018-01-24 Applied Proteomics Inc Methods of assessing colorectal cancer status
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
CA3029926C (en) * 2016-07-25 2023-01-03 Shizuoka Prefecture Diagnostic biomarker for extrahepatic bile duct cancer, intrahepatic bile duct cancer or gallbladder cancer
WO2018111989A1 (en) 2016-12-14 2018-06-21 Purdue Research Foundation Fibroblast activation protein (fap)-targeted imaging and therapy
DE102017010455A1 (de) * 2017-06-13 2018-12-13 Forschungszentrum Jülich GmbH Verfahren zum Nachweis von Aggregaten biotherapeutischer Substanzen in einer Probe
CA3074684A1 (en) * 2017-09-05 2019-03-14 Oncotag Diagnostics Co., Ltd. Method for diagnosing pancreatic cancer using methionyl-trna synthetase, and pancreatic cancer diagnostic kit using same
WO2022007283A1 (zh) * 2020-07-08 2022-01-13 深圳霁因生物医药转化研究院 用于诊断fap表达异常相关疾病的试剂盒、方法及计算机可读存储介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
CN104531529A (zh) * 2003-10-31 2015-04-22 维特克公司 用于检测循环肿瘤和内皮细胞的血液测试样机和方法
US7968308B2 (en) * 2004-10-22 2011-06-28 Danisco Us Inc. Isolating human antibodies
EP1760076A1 (en) * 2005-09-02 2007-03-07 Ferring B.V. FAP Inhibitors
CA2633803A1 (en) * 2005-12-19 2007-09-07 Trustees Of Tufts College Soft protease inhibitors and pro-soft forms thereof

Also Published As

Publication number Publication date
US20100240081A1 (en) 2010-09-23
EP2223115A1 (en) 2010-09-01
JP2011506941A (ja) 2011-03-03
KR101202220B1 (ko) 2012-11-16
ATE524740T1 (de) 2011-09-15
EP2223115B1 (en) 2011-09-14
WO2009074275A1 (en) 2009-06-18
AU2008335855B2 (en) 2012-08-30
PL2223115T3 (pl) 2012-02-29
CN101896818B (zh) 2016-01-20
HK1150884A1 (zh) 2012-01-13
CN101896818A (zh) 2010-11-24
US8980573B2 (en) 2015-03-17
DK2223115T3 (da) 2011-12-12
ES2372442T3 (es) 2012-01-19
CA2706115A1 (en) 2009-06-18
JP5563988B2 (ja) 2014-07-30
MX2010004671A (es) 2010-05-27
KR20100091212A (ko) 2010-08-18
AU2008335855A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
BRPI0820793A2 (pt) Seprase como marcador de câncer
WO2010072383A8 (en) Armet as a marker for cancer
ES2505466T3 (es) Procedimientos para predecir la respuesta al tratamiento del cáncer de mama triple negativo
ATE554389T1 (de) Apex als marker für lungenkrebs
ES2683362T3 (es) Microvesículas obtenidas a partir de células tumorales
DE602006018578D1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
WO2014140933A3 (en) Method for the prognosis and treatment of cancer metastasis
JP2011521618A5 (enExample)
WO2006091412A3 (en) Adamts-7 as a biomarker for cancers of epithelial origin
WO2010017515A3 (en) Breast cancer specific markers and methods of use
SI2138848T1 (sl) Postopek za diagnozo in/ali prognozo raka mehurja
EA201490946A1 (ru) Способ количественной оценки лечения рака
FI2398902T3 (fi) Menetelmiä ja koostumuksia syövän diagnoosia ja hoitoa varten
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2010051314A3 (en) Genomic classification of non-small cell lung carcinoma based on patterns of gene copy number alterations
IL201778A0 (en) Peptide imaging agents
EA200801046A1 (ru) Неинвазивный способ выявления переходно-клеточной карциномы мочевого пузыря in vitro
ATE471512T1 (de) Verwendung des proteins s100a 12 als marker für kolorektalkarzinom
JP2015007118A5 (enExample)
WO2009015294A8 (en) Biomarkers for human papillomavirus-associated cancers
WO2020012367A3 (en) Dna methylation markers for noninvasive detection of cancer and uses thereof
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
CA2967867C (en) Methods for detection and treatment of colorectal cancer
ATE459883T1 (de) Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose
Tirelli et al. Open questions and novel concepts in oral cancer surgery

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]